- Home
- SGA vs CUE Comparison
SGA vs CUE Comparison
Compare SGA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- CUE
- Stock Information
- Founded
- SGA 1986
- CUE 2014
- Country
- SGA United States
- CUE United States
- Employees
- SGA N/A
- CUE N/A
- Industry
- SGA Broadcasting
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- CUE Health Care
- Exchange
- SGA Nasdaq
- CUE Nasdaq
- Market Cap
- SGA 72.0M
- CUE 77.3M
- IPO Year
- SGA 1992
- CUE 2018
- Fundamental
- Price
- SGA $12.03
- CUE $1.21
- Analyst Decision
- SGA
- CUE Strong Buy
- Analyst Count
- SGA 0
- CUE 5
- Target Price
- SGA N/A
- CUE $5.00
- AVG Volume (30 Days)
- SGA 40.6K
- CUE 389.8K
- Earning Date
- SGA 03-06-2025
- CUE 03-10-2025
- Dividend Yield
- SGA 8.18%
- CUE N/A
- EPS Growth
- SGA N/A
- CUE N/A
- EPS
- SGA 0.75
- CUE N/A
- Revenue
- SGA $110,669,000.00
- CUE $9,532,000.00
- Revenue This Year
- SGA N/A
- CUE $73.11
- Revenue Next Year
- SGA $2.64
- CUE $11.02
- P/E Ratio
- SGA $16.28
- CUE N/A
- Revenue Growth
- SGA N/A
- CUE 149.53
- 52 Week Low
- SGA $10.75
- CUE $0.45
- 52 Week High
- SGA $24.70
- CUE $2.93
- Technical
- Relative Strength Index (RSI)
- SGA 53.31
- CUE 48.27
- Support Level
- SGA $11.57
- CUE $1.21
- Resistance Level
- SGA $12.00
- CUE $1.75
- Average True Range (ATR)
- SGA 0.40
- CUE 0.19
- MACD
- SGA 0.11
- CUE -0.01
- Stochastic Oscillator
- SGA 85.37
- CUE 32.50
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets and It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.